The Real Story cover image

How close are we to ending Alzheimer's?

The Real Story

00:00

The Clinical Benefits of Two New Drugs

Durnanamab and Lekenamab looked at PET scans that measure amyloid primarily in its plaque form. They attempted to lower the amount of plaque amyloid that you can see on the scan. That was an important aspect of starting to show some clinical benefit. John Hardy: It gives us a roadmap. We now know what other drugs need to do. And it should really speed up research into finding other drugs, too.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app